<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675788</url>
  </required_header>
  <id_info>
    <org_study_id>2005890134</org_study_id>
    <secondary_id>1R01HL153114-01</secondary_id>
    <nct_id>NCT04675788</nct_id>
  </id_info>
  <brief_title>Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening</brief_title>
  <official_title>Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Purdue University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research will determine if: 1) Oral progesterone attenuates drug-induced QT interval,&#xD;
      J-Tpeak and Tpeak-Tend lengthening in postmenopausal women 50 years of age or older, and 2)&#xD;
      Transdermal testosterone attenuates drug-induced QT interval, J-Tpeak and Tpeak-Tend&#xD;
      lengthening in men 65 years of age or older. This investigation will consist of two&#xD;
      concurrent prospective, randomized, double-blind, placebo-controlled crossover-design studies&#xD;
      in a) Postmenopausal women, and b) Men 65 years of age or older. Study 1: Each postmenopausal&#xD;
      woman will take progesterone or placebo capsules for 1 week. After a 14-day &quot;washout&quot; (no&#xD;
      progesterone or placebo) each subject will then take the alternative therapy (progesterone or&#xD;
      placebo) for 1 week. After 7 days of each treatment, subjects will present to the clinical&#xD;
      research center to receive a small dose of the QT interval-lengthening drug ibutilide, and&#xD;
      the effect on the QT, J-Tpeak and Tpeak-Tend intervals during the progesterone and placebo&#xD;
      phases will be compared. Study 2: Each man 65 years of age or older will apply transdermal&#xD;
      testosterone or transdermal placebo gel for 3 days. After a 7-day &quot;washout&quot; (no testosterone&#xD;
      or placebo) each subject will then apply the alternative therapy (testosterone or placebo&#xD;
      gel) for 1 week. After 3 days of each treatment, subjects will present to the clinical&#xD;
      research center to receive a small dose of the QT interval-lengthening drug ibutilide, and&#xD;
      the effect on the QT, J-Tpeak and Tpeak-Tend intervals during the testosterone and placebo&#xD;
      phases will be compared.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Torsades de pointes (TdP) is a ventricular tachycardia associated with prolongation of the&#xD;
      corrected QT (QTc) interval, and which may be caused by &gt; 150 widely used drugs. TdP results&#xD;
      in catastrophic outcomes, including sudden cardiac death. Older age is a risk factor for&#xD;
      drug-induced TdP, possibly due to declining serum progesterone and testosterone&#xD;
      concentrations in postmenopausal women and men, respectively. The ECG biomarkers J-Tpeak and&#xD;
      Tpeak-Tend, represent early and late repolarization, respectively, as well as dispersion of&#xD;
      repolarization (Tpeak-Tend). Preclinical evidence and preliminary data from our group&#xD;
      indicate that progesterone and testosterone exert protective effects against drug-induced&#xD;
      prolongation of ventricular repolarization. Effective means of reducing the risk of&#xD;
      drug-induced QTc interval prolongation and TdP in high risk populations requiring therapy&#xD;
      with QTc-prolonging drugs have not been identified, and the effects of sex hormones on early&#xD;
      vs late ventricular repolarization and dispersion of repolarization are unknown. The&#xD;
      objectives of this research are to evaluate novel therapeutic approaches to attenuate&#xD;
      drug-induced QTc lengthening. Our central hypothesis is that drug-induced QTc lengthening is&#xD;
      attenuated by administration of oral progesterone and transdermal testosterone. Specific Aim&#xD;
      1: Determine the efficacy of oral progesterone as a preventive method to attenuate&#xD;
      drug-induced QTc interval lengthening in postmenopausal women. Specific Aim 2: Determine the&#xD;
      efficacy of transdermal testosterone as a preventive method to attenuate drug-induced QTc&#xD;
      interval lengthening in men ≥ 65 years of age. Specific Aim 3a: Determine the influence of&#xD;
      oral progesterone on drug-induced lengthening of early and late ventricular repolarization in&#xD;
      postmenopausal women. Specific Aim 3b: Determine the influence of transdermal testosterone on&#xD;
      drug-induced lengthening of early and late ventricular repolarization in men ≥ 65 years of&#xD;
      age. Specific Aims 1&amp;3a will be achieved via a prospective, randomized, double-blind,&#xD;
      placebo-controlled two-way crossover study in postmenopausal women age ≥ 50 years (n=48).&#xD;
      Each subject will take oral progesterone 400 mg or matching placebo daily for 7 days (≥&#xD;
      14-day washout period between phases). On day 7, each subject will receive a single dose of&#xD;
      the QTc-lengthening drug ibutilide 0.003 mg/kg. Specific Aims 2&amp;3b will be achieved via a&#xD;
      prospective, randomized, double-blind, placebo-controlled two-way crossover study in men ≥ 65&#xD;
      years of age (n=35). Each subject will apply transdermal testosterone 1% 100 mg or&#xD;
      transdermal placebo once daily for 3 days (≥ 7-day washout period between phases). On day 7,&#xD;
      each subject will ibutilide 0.003 mg/kg. In both studies, post-ibutilide QT, J-Tpeak and&#xD;
      Tpeak-Tend intervals and serum ibutilide concentrations will be determined serially. Primary&#xD;
      outcome measures: 1) Maximum post-ibutilide QTc intervals, 2) Maximum post-ibutilide % change&#xD;
      in QTc intervals, 3) Area under the QTc interval-time curves, and 4) J-Tpeak and Tpeak-Tend&#xD;
      intervals. This research will identify effective approaches for reducing the risk of&#xD;
      drug-induced QTc interval prolongation in high-risk patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-ibutilide QT-F and QT-Fram intervals</measure>
    <time_frame>Morning of day 8 (after 7 days of progesterone/placebo)</time_frame>
    <description>QT intervals will be corrected for heart rate using two methods: the Fridericia method and the Framingham method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre-ibutilide QT-F and QT-Fram intervals</measure>
    <time_frame>Morning of day 4 (after 3 days of testosterone/placebo)</time_frame>
    <description>QT intervals will be corrected for heart rate using two methods: the Fridericia method and the Framingham method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum post-ibutilide QT-F and QT-Fram intervals</measure>
    <time_frame>From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion</time_frame>
    <description>Maximum post-ibutilide QT-F and QT-Fram intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline (pre-ibutilide) in maximum QT-F and QT-Fram intervals</measure>
    <time_frame>From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion</time_frame>
    <description>Percent change from baseline (pre-ibutilide) in maximum QT-F and QT-Fram intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the QT-F and QT-Fram versus time curves during and for 1 hour following ibutilide infusion</measure>
    <time_frame>From initiation of ibutilide infusion and for 1 hour after the end of ibutilide infusion</time_frame>
    <description>Area under the QT-F and QT-Fram versus time curves during and for 1 hour</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the QT-F and QT-Fram versus time curves during and for 8 hours following ibutilide infusion</measure>
    <time_frame>From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion</time_frame>
    <description>Area under the QT-F and QT-Fram versus time curves during and for 8 hours following ibutilide infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre-ibutilide heart rate-corrected J-Tpeak (J-Tpeakc) intervals</measure>
    <time_frame>Morning of day 8 (after 7 days of progesterone/placebo)</time_frame>
    <description>Pre-ibutilide heart rate-corrected J-Tpeak (J-Tpeakc) intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre-ibutilide heart rate-corrected J-Tpeak (J-Tpeakc) intervals</measure>
    <time_frame>Morning of day 4 (after 3 days of testosterone/placebo)</time_frame>
    <description>Pre-ibutilide heart rate-corrected J-Tpeak (J-Tpeakc) intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum post-ibutilide J-Tpeakc intervals</measure>
    <time_frame>From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion</time_frame>
    <description>Maximum post-ibutilide J-Tpeakc intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline (pre-ibutilide) in maximum J-Tpeakc intervals</measure>
    <time_frame>From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion</time_frame>
    <description>Percent change from baseline (pre-ibutilide) in maximum J-Tpeakc intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the J-Tpeakc versus time curve during and for 1 hour following ibutilide infusion</measure>
    <time_frame>From initiation of ibutilide infusion and for 1 hour after the end of ibutilide infusion</time_frame>
    <description>Area under the J-Tpeakc versus time curve during and for 1 hour following ibutilide infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the J-Tpeakc versus time curve during and for 8 hours following ibutilide infusion</measure>
    <time_frame>From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion</time_frame>
    <description>Area under the J-Tpeakc versus time curve during and for 8 hours following ibutilide infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre-ibutilide Tpeak-Tend intervals</measure>
    <time_frame>Morning of day 8 (after 7 days of progesterone/placebo)</time_frame>
    <description>Pre-ibutilide Tpeak-Tend intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre-ibutilide Tpeak-Tend intervals</measure>
    <time_frame>Morning of day 4 (after 3 days of testosterone/placebo)</time_frame>
    <description>Pre-ibutilide Tpeak-Tend intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum post-ibutilide Tpeak-Tend intervals</measure>
    <time_frame>From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion</time_frame>
    <description>Maximum post-ibutilide Tpeak-Tend intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline (pre-ibutilide) maximum Tpeak-Tend intervals</measure>
    <time_frame>From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion</time_frame>
    <description>Percent change from baseline (pre-ibutilide) maximum Tpeak-Tend intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Tpeak-Tend versus time curves during and for 1 hour following ibutilide infusion</measure>
    <time_frame>From initiation of ibutilide infusion and for 1 hour after the end of ibutilide infusion</time_frame>
    <description>Area under the Tpeak-Tend versus time curves during and for 1 hour following ibutilide infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Tpeak-Tend versus time curves during and for 8 hours following ibutilide infusion</measure>
    <time_frame>From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion</time_frame>
    <description>Area under the Tpeak-Tend versus time curves during and for 8 hours following ibutilide infusion</description>
  </primary_outcome>
  <other_outcome>
    <measure>Adverse effects of oral progesterone and placebo</measure>
    <time_frame>Adverse effects will be assessed via telephone calls to subjects between days 2 and 4 and between days 5 and 7 of oral progesterone and oral placebo</time_frame>
    <description>Adverse effects of oral progesterone and oral placebo</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse effects of transdermal testosterone and transdermal placebo</measure>
    <time_frame>Adverse effects will be assessed via telephone calls to subjects between days 1 and 3 of transdermal testosterone and transdermal placebo</time_frame>
    <description>Adverse effects of transdermal testosterone and transdermal placebo</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse effects of ibutilide</measure>
    <time_frame>Adverse effects of ibutilide will be assessed during the 10-minute intravenous infusion and for 8 hours following the infusion of ibutilide</time_frame>
    <description>Adverse effects of ibutilide</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Long QT Syndrome</condition>
  <condition>Abnormalities, Drug-Induced</condition>
  <arm_group>
    <arm_group_label>Postmenopausal women: Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postmenopausal women: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive oral placebo, two capsules once daily every evening for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Men 65 years of age or older: Testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive treatment with transdermal testosterone 1% (100 mg) every morning for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Men 65 years of age or older: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive treatment with transdermal placebo every morning for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days</description>
    <arm_group_label>Postmenopausal women: Progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibutilide</intervention_name>
    <description>Ibutilide 0.003 mg/kg administered to all subjects to modestly lengthen the QT interval</description>
    <arm_group_label>Men 65 years of age or older: Placebo</arm_group_label>
    <arm_group_label>Men 65 years of age or older: Testosterone</arm_group_label>
    <arm_group_label>Postmenopausal women: Placebo</arm_group_label>
    <arm_group_label>Postmenopausal women: Progesterone</arm_group_label>
    <other_name>Corvert</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Subjects will apply transdermal testosterone gel once daily every morning for 3 days</description>
    <arm_group_label>Men 65 years of age or older: Testosterone</arm_group_label>
    <other_name>Androgel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lactose capsules</description>
    <arm_group_label>Men 65 years of age or older: Placebo</arm_group_label>
    <arm_group_label>Postmenopausal women: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Postmenopausal Women:&#xD;
&#xD;
          -  Age ≥ 50 years old&#xD;
&#xD;
          -  Postmenopausal (have not has a menstrual period for 12 months or longer)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Postmenopausal women:&#xD;
&#xD;
          -  Subject reported history of breast, uterine and ovarian cervical cancer&#xD;
&#xD;
          -  Subject reported history of hysterectomy and/or ovariectomy&#xD;
&#xD;
          -  Subject reported taking any hormone replacement therapy (prescription, nonprescription&#xD;
             or herbal supplement)&#xD;
&#xD;
          -  Weight &lt; 60 kg at time of screening visit&#xD;
&#xD;
          -  Weight &gt;135 kg at time of screening visit&#xD;
&#xD;
          -  Serum K+ &lt;3.6 mEq/L at time of any ibutilide dosing visit&#xD;
&#xD;
          -  Serum Mg2+ &lt;1.8 mg/dL at time of screening visit&#xD;
&#xD;
          -  Hematocrit &lt;26%&#xD;
&#xD;
          -  AST or ALT &gt; 3x the upper limit of normal (determined by testing lab ranges) at the&#xD;
             time of screening visit&#xD;
&#xD;
          -  Baseline Bazett's-corrected QTc &gt;450 ms (during any visit prior to ibutilide dosing)&#xD;
&#xD;
          -  Baseline QRS &gt; 120 ms (at time of baseline visit)&#xD;
&#xD;
          -  Diagnosis of heart failure due to reduced or preserved ejection fraction&#xD;
&#xD;
          -  Subject reported family history of long QT syndrome, TdP, or sudden cardiac death not&#xD;
             associated with acute myocardial infarction&#xD;
&#xD;
          -  Self-reported personal history of long QT syndrome, sudden cardiac death not&#xD;
             associated with acute myocardial infarction&#xD;
&#xD;
          -  Subject reported history any prolonged arrhythmia for which treatment was required&#xD;
&#xD;
          -  Subject reported history of a myocardial infarction&#xD;
&#xD;
          -  Subject reported history of coronary artery disease&#xD;
&#xD;
          -  Sustained arrythmia found at baseline screening prior to any study visit including&#xD;
             atrial fibrillation, atrial flutter, junctional rhythm, heart block (any)&#xD;
&#xD;
          -  Permanently paced ventricular rhythm&#xD;
&#xD;
          -  Current reported use of any QT prolonging medication. Investigator will check the&#xD;
             current QT drugs list at www.crediblemeds.org during screening.&#xD;
&#xD;
          -  Current reported use of any moderate or strong inhibitors of cytochrome P450 (CYP)&#xD;
             3A4, 3A5, or 3A7&#xD;
&#xD;
          -  Current reported use of any inducers of cytochrome P-450 (CYP) 3A4, 3A5 or 3A7&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        Older Men:&#xD;
&#xD;
        • Age ≥ 65 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Older men:&#xD;
&#xD;
          -  Subject reported diagnosis of benign prostatic hyperplasia&#xD;
&#xD;
          -  Subject reported history of breast or prostate cancer&#xD;
&#xD;
          -  Weight &lt; 60 kg at time of screening visit&#xD;
&#xD;
          -  Weight &gt;135 kg at time of screening visit&#xD;
&#xD;
          -  Serum K+ &lt;3.6 mEq/L at time of any ibutilide dosing visit&#xD;
&#xD;
          -  Serum Mg2+ &lt;1.8 mg/dL at time of screening visit&#xD;
&#xD;
          -  Hematocrit &lt;26%&#xD;
&#xD;
          -  AST or ALT &gt; 3x the upper limit of normal (determined by testing lab ranges) at the&#xD;
             time of screening visit&#xD;
&#xD;
          -  Baseline Bazett's-corrected QTc &gt;450 ms (during any visit prior to ibutilide dosing)&#xD;
&#xD;
          -  Baseline QRS &gt; 120 ms (at time of baseline visit)&#xD;
&#xD;
          -  Diagnosis of heart failure due to reduced or preserved ejection fraction&#xD;
&#xD;
          -  Subject reported family history of long QT syndrome, TdP, or sudden cardiac death not&#xD;
             associated with acute myocardial infarction&#xD;
&#xD;
          -  Self-reported personal history of long QT syndrome, arrhythmias (including atrial&#xD;
             fibrillation) or sudden cardiac death not associated with acute myocardial infarction&#xD;
&#xD;
          -  Sustained arrythmia found at baseline screening prior to any study visit including&#xD;
             atrial fibrillation, atrial flutter, junctional rhythm, heart block (any)&#xD;
&#xD;
          -  Permanently paced ventricular rhythm&#xD;
&#xD;
          -  Current reported use of any QT prolonging medication (Investigator will check current&#xD;
             list of QT prolonging medications listed at www.crediblemeds.org at the time of&#xD;
             screening for the most up to date list.&#xD;
&#xD;
          -  Current reported use of any moderate or strong inhibitors of cytochrome P450 (CYP) 3A&#xD;
&#xD;
          -  Current reported use of any inducers of cytochrome P-450 (CYP) 3A4, 3A5 or 3A7&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James E Tisdale, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Purdue University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James E Tisdale, PharmD</last_name>
    <phone>317-880-5418</phone>
    <email>jtisdale@purdue.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather A Jaynes, MSN</last_name>
    <phone>317-847-2094</phone>
    <email>hwroblew@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana Clinical Research Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Denne, MD</last_name>
      <phone>317-274-4920</phone>
      <email>sdenne@iupui.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Cromer</last_name>
      <phone>317-278-3446</phone>
      <email>scromer2@iupui.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James E Tisdale, BSC, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heather Jaynes, MSN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard J Kovacs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin M Sowinski, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Flockhart, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James E Tisdale, PharmD</last_name>
      <phone>317-880-5418</phone>
      <email>jtisdale@purdue.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Purdue University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James E Tisdale, BSc, PharmD</last_name>
      <phone>317-880-5418</phone>
      <email>jtisdale@purdue.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather Jaynes, MSN</last_name>
      <phone>317-847-2094</phone>
      <email>hwroblew@iu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James E Tisdale, BSc, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian R Overholser, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heather A Jaynes, MSN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard J Kovacs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin M Sowinski, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>James E. Tisdale</investigator_full_name>
    <investigator_title>Professor of PharmD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Long QT Syndrome</mesh_term>
    <mesh_term>Abnormalities, Drug-Induced</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibutilide</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

